How much is the empagliflozin, dapagliflozin and canagliflozin market worth, and how is it expected to expand?
The empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from $9.64 billion in 2024 to $9.94 billion in 2025 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to the increase in the prevalence of type 2 diabetes globally, increased awareness about the benefits of SGLT2 inhibitors, growth in the elderly population, growth in the prevalence of obesity, and increase in focus on personalized medicine.
The empagliflozin, dapagliflozin and canagliflozin market size is expected to see steady growth in the next few years. It will grow to $11.06 billion in 2029 at a compound annual growth rate (CAGR) of 2.7%. The growth in the forecast period can be attributed to increasing demand for oral diabetes medications, increasing investments in diabetes research and drug development, increasing healthcare expenditure, rising awareness and diagnosis of pre-diabetes conditions, and increasing focus on combination therapies. Major trends in the forecast period include technological advancements, combination therapies, telehealth, health data analytics, and patient data security.
Get Your Free Sample of The Global Empagliflozin, Dapagliflozin And Canagliflozin Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18350&type=smp
How has the empagliflozin, dapagliflozin and canagliflozin market evolved, and what factors have shaped its growth?
The increasing prevalence of diabetes is expected to propel the growth of the empagliflozin, dapagliflozin, and canagliflozin market going forward. Diabetes presents as a persistent health issue marked by high blood sugar levels stemming from inadequate insulin production or the body’s ineffective utilization of insulin. The increasing prevalence of diabetes can be attributed to factors such as sedentary lifestyles, unhealthy dietary habits, genetic predisposition, urbanization, and aging populations, compounded by limited access to healthcare and rising obesity rates worldwide. Empagliflozin, dapagliflozin, and canagliflozin are used in diabetes management to lower blood sugar levels by inhibiting sodium-glucose co-transporter-2 (SGLT2) in the kidneys, promoting the excretion of glucose through urine. For instance, in June 2024, according to the National Health Service (NHS), UK-based government department, among individuals under 40, rising from 173,166 in 2022 to 216,440 in 2023. This significant growth highlights a concerning trend in this age group. The data reflects a rapid escalation in diabetes prevalence among younger populations. Therefore, the increasing prevalence of diabetes is driving the growth of the empagliflozin, dapagliflozin, and canagliflozin market.
What are the major segments of the empagliflozin, dapagliflozin and canagliflozin market?
The empagliflozin, dapagliflozin and canagliflozin market covered in this report is segmented –
1) By Type: Empagliflozin, Dapagliflozin, Canagliflozin
2) By Application: Application I, Application II, Application III, Application IV
3) By Channel: Hospital, Pharmacy
Subsegments:
1) Empagliflozin: 10 Mg, 25 Mg, 50 Mg
2) Dapagliflozin: 5 Mg, 10 Mg
3) Canagliflozin: 100 Mg, 300 Mg
Order your report now for swift delivery
Which companies dominate the empagliflozin, dapagliflozin and canagliflozin market?
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.
How will evolving trends contribute to the growth of the empagliflozin, dapagliflozin and canagliflozin market?
Major companies operating in the empagliflozin, dapagliflozin, and canagliflozin markets are focusing on developing innovative products, such as pediatric type-2 diabetes treatment, to address broader patient demographics and expand their market reach in diabetes care. Pediatric Type-2 diabetes treatment involves managing blood sugar levels through lifestyle changes, medications, and sometimes insulin therapy tailored specifically for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 years and older with type 2 diabetes. This approval is based on positive results from the T2NOW Phase III clinical trial, one of the most extensive pediatric type-2 diabetes trials to date, which showed that Farxiga significantly reduced HbA1c levels compared to placebo. The safety profile of Farxiga in this patient population was consistent with that observed in adults with type-2 diabetes. This approval is an important milestone, as oral treatment options for pediatric type-2 diabetes have been limited, and it underscores AstraZeneca’s commitment to delivering innovative treatments across cardiovascular, renal, and metabolic diseases.
What are the key regional dynamics of the empagliflozin, dapagliflozin and canagliflozin market, and which region leads in market share?
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Empagliflozin, Dapagliflozin And Canagliflozin Market Report 2025 Offer?
The empagliflozin, dapagliflozin and canagliflozin market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Empagliflozin, dapagliflozin, and canagliflozin are medications classified as sodium-glucose co-transporter-2 (SGLT-2) inhibitors primarily used in treating type 2 diabetes mellitus. These medications are taken orally and are part of a broader diabetes management plan that includes diet, exercise, and other medications as needed.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18350
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
